Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Molecular Partners Ag ADR
(NQ:
MOLN
)
5.800
+0.810 (+16.23%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Jun 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
38,056
Open
5.880
Bid (Size)
5.880 (1)
Ask (Size)
6.080 (1)
Prev. Close
4.990
Today's Range
5.800 - 6.110
52wk Range
3.320 - 6.800
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Today 8:06 EDT
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Today 7:46 EDT
Pre-market stock movers are worth checking out as we dive into all of the biggest news sending shares higher and lower on Wednesday morning!
Via
InvestorPlace
Performance
YTD
+39.09%
+39.09%
1 Month
+63.49%
+63.49%
3 Month
+55.50%
+55.50%
6 Month
+49.40%
+49.40%
1 Year
-14.07%
-14.07%
More News
Read More
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
June 11, 2024
From
Molecular Partners
Via
GlobeNewswire
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 03, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
June 03, 2024
Via
Benzinga
Why GameStop Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
June 03, 2024
Via
Benzinga
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
June 01, 2024
From
Molecular Partners
Via
GlobeNewswire
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
May 16, 2024
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action
April 29, 2024
From
Molecular Partners
Via
GlobeNewswire
Life Science Cares Launches in Switzerland
April 19, 2024
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
April 17, 2024
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Publishes Invitation to Annual General Meeting 2024
March 26, 2024
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
March 14, 2024
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Announces Dismissal of Class Action Lawsuit
March 01, 2024
From
Molecular Partners
Via
GlobeNewswire
Earnings Scheduled For March 14, 2024
March 14, 2024
Via
Benzinga
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
March 01, 2024
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
January 07, 2024
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
January 05, 2024
From
Molecular Partners
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
January 04, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 03, 2024
Via
Benzinga
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences
December 14, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
December 10, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
November 14, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
November 03, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
November 02, 2023
From
Molecular Partners
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.